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Introduction
The product of the p53 gene is capable of inducing transcription 
activation or repression of a variety of genes, which in turn  trigger 
cell cycle arrest and promote apoptosis, differentiation, or senes-
cence (Vousden and Prives, 2005). p53 levels and activity are 
regulated by numerous stress-induced posttranslational modifi -
cations that converge on two distinct domains of the protein 
 (Appella and Anderson, 2001). A kinase cascade phosphory lates 
several serine residues in the p53 NH2-terminal region. Among 
these, phosphorylation of serine 15, 20, and 46 and threonine 18 
are of most signifi cance, as they act by promoting p53 stabiliza-
tion (Unger et al., 1999; Knights et al., 2003), by preventing 
 nuclear export (Zhang and Xiong, 2001), or by favoring p53 re-
cruitment on specifi c sets of promoters (Oda et al., 2000). A sec-
ond pathway targets the p53 COOH terminus and involves the 
activity of at least two classes of acetyltransferases, p300/CBP 
and p300/CBP-associated factor (PCAF; Avantaggiati et al., 
1997; Lill et al., 1997). p300/CBP acetylates lysines located in 
the last COOH-terminal portion of p53, specifi cally, lysines 370, 
372, 373, and 382 (Gu and Roeder, 1997). PCAF has been linked 
to acetylation of a single residue, lysine 320, located within a 
fl exible linker domain nearby the oligomerization domain, which 
also contains a nuclear localization signal (Sakaguchi et al., 1998; 
Liu et al., 1999). These initial studies demonstrated that all these 
acetylation events lead to enhancement of p53 DNA binding 
 activity in vitro. More recently, acetylation has been shown to 
stimulate the p53–DNA interaction in vivo as well (Luo et al., 
2004), in agreement with the original proposal that acetylation 
relieves the inhibitory role exerted by the COOH terminus on p53 
DNA binding capacity (Prives and Manley, 2001; Luo et al., 
2004). However, thus far, the biological signifi cance of individual 
acetylation of each of these lysine clusters is unclear.
The proapoptotic activity is the most ancestral function of 
p53, but additional and more complex activities have clearly ap-
peared during evolution. This is argued based on the properties 
of the p53 protein of Drosophila melanogaster, dp53, which dif-
fers from its human counterpart because of its exclusive role in 
promoting apoptosis. Similarly, the Caenorhabditis elegans ho-
mologue of p53, CEP-1, displays predominantly proapoptotic 
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activity (Derry et al., 2001). The evolution of p53 toward cell 
cycle regulatory functions in complex multicellular organisms 
may refl ect the need of cells to deal with various forms of stress 
in a more advantageous fashion and to mount adaptive responses 
that preserve the life of tissues with limited proliferative potential. 
In fact, in mammalian cells, the effects of p53 on cellular growth 
are pleiotropic and exhibit cell type specifi cities, and the p53-
 induced cell cycle arrest, although prolonged, is often reversible 
(Bates et al., 1999). This reversibility is presumably important 
in conditions of “repairable” cellular damage, for resumption of 
proliferation when apoptosis can be avoided. Yet, the molecular 
basis for p53’s ability to commit cells toward these different 
 outcomes is still an object of intense investigation. Given the 
large repertoire of p53-responsive genes, one possibility is that 
a particular combination of target genes, activated or repressed, 
may determine whether cells will survive or die after engage-
ment of p53 activity. Because cells are continuously exposed to 
genotoxic signals of different nature and intensity, they must 
have elaborated ways that allow p53 to interact with specifi c 
classes of genes but not with others, ultimately leading to adap-
tation and differential susceptibility to stress.
How, then, does p53 select such combination patterns? 
 Important determinants of selectivity are likely the accessibility of 
chromatin and the structural characteristics of the DNA consensus 
sequences within p53-responsive elements, which show a surpris-
ingly high degree of variation (Resnick and Inga, 2003; Tomso 
et al., 2005). When several p53-response elements were analyzed 
for their ability to be activated in a yeast-based assay that elimi-
nates the infl uence of chromatin on transcription, an unexpected 
1,000-fold difference in p53 transactivation ability was detected 
depending on the central sequence present within each response 
element. In addition, tumor-derived p53 mutants that have altered 
conformation compared with the wild-type (WT) protein exhibit 
distinct promoter specifi cities and retain their ability to transacti-
vate certain promoters but not others. Thus, the intrinsic DNA 
binding affi nity of p53, together with conformational changes, 
may contribute to differential gene activation. Posttranslational 
modifi cations may play an important role in modifying both p53 
conformation and p53 affi nity for its downstream targets.
In this study, we have characterized the functional and 
biochemical properties of p53 mutants mimicking constitutive 
acetylation as well as of truly acetylated p53. We show that two 
distinct acetylable clusters at position 373 (K373) and 320 
(K320) regulate p53 activity in quite a different fashion. 
A model is proposed to explain how site-specifi c acetylation 
operates and cross-talks with other events, such as additional 
posttranslational modifi cations and protein–protein  interactions, 
to modify p53 affi nity for different classes of genes during stress 
signals, leading to cell survival or death.
Results
Different kinetics of acetylation of K320 
and K373 in response to DNA damage
We began our studies by asking how acetylation of different 
sites is regulated during stress signals. For these experiments we 
used a p53-null, human lung carcinoma cell line, H1299, where 
the expression of p53 was reconstituted via a tetracycline-
 inducible vector. The kinetics of acetylation of K320 and K373 
were then studied in cells exposed to the radiomimetic DNA-
 alkylating agents adozelesin and bizelesin or to the topoisomer-
ase inhibitor etoposide. Adozelesin and bizelesin are members 
of the cyclopropylpyrroloindole (CPI) family of DNA minor 
groove alkylating agents endowed with anti-tumor activity (Lee 
et al., 1994). Adozelesin is a monofunctional CPI, whereas bize-
lesin is a CPI dimer that can alkylate adenines on one or both 
DNA strands, forming double-stranded DNA cross-links that 
render it more cytotoxic than adozelesin. Thus, these drugs al-
lowed us to assess whether different types of DNA damage trigger 
distinct acetylation events. In cells treated with adozelesin, which 
arrested predominantly in G1 and did not undergo apoptosis 
(Fig. 1 A), acetylation of K373 was no longer visible after 4–12 h 
of treatment, whereas acetylation of K320 remained detectable for 
24 h after the addition of the drug (Fig. 1 B). In contrast, treatment 
with bizelesin or etoposide resulted in robust and sustained levels 
of acetylation of K373 and induced an initial arrest in G2/M 
 followed by apoptosis (Fig. 1 A and not depicted).
These results provided evidence that the kinetics of K320 
and K373 acetylation can be dissected depending on the type 
Figure 1. The kinetics of K320 and K373 acetylation of p53 in response 
to DNA damage correlate with cell cycle arrest or apoptosis. (A) Cell cycle 
proﬁ le of H1299 cells expressing tetracycline-inducible p53. Cells were 
left untreated or treated with 5 μM adozelesin or bizelesin or with 100 μM 
etoposide after a 24-h induction of p53 with tetracycline. Flow cytometry 
was performed as described previously (Avantaggiati et al., 1997). The 
percentage of cells displaying Sub-G1, G1, S, or G2/M DNA content is 
provided as an inset for each histogram. (B) H1299 cells expressing p53 
were treated as indicated at the top of each panel in A. At different times 
after treatment, cells were harvested and cell lysates were immunoprecipi-
tated with a polyclonal antibody recognizing acetyl-p53K320 (Acp53K320) 
or acetyl-p53K373 (Acp53K373) or with an antibody recognizing total p53, 
as indicated on the left side of each panel. The products of these reactions 
were then subjected to immunoblot with a mixture of monoclonal anti-
bodies directed against the p53 NH2 terminus (DO-1) and COOH terminus 
(PAb421). Black lines indicate that intervening lanes have been spliced out. 
(C) H1299 cells expressing WT p53 were left untreated or treated with 
 increasing concentrations of adozelesin or bizelesin (1, 50, or 500 μM), 
harvested after 6 h, and analyzed as in B.
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of damage. To test whether the amount of DNA damage also 
 infl uences the extent and sites of acetylation, we treated cells 
expressing p53 with increasing doses of adozelesin or bizelesin 
(Fig. 1 C). In this case, we observed a dose-dependent enrich-
ment of the levels of K373 acetylation, whereas acetylation of 
K320 was only modestly enhanced. Thus, various acetylation 
sites act as a “sensor” system for the type and extent of DNA 
damage and may differentially regulate the ability of p53 to 
 induce cell cycle arrest or apoptosis.
Opposing effects of K320 and K373 
acetylation on the ability of p53 
to induce apoptosis
To gain more insights into the function of acetylation, we created 
gain-of-function p53 acetylation mutants. Glutamine in place of 
lysine has been shown to mimic the effects of a constitutive acety-
lation in the case of histones and of p53 (Luo et al., 2004), prob-
ably because glutamine is a neutral amino acid, which, like 
N-acetyl-lysine, has an amide group that can function as a hydro-
gen bond donor or acceptor. Thus, we constructed mutants har-
boring lysine to glutamine substitutions at position 320 (Q320), 
a triple mutant at position 370/372/373 (Q373), or at all these 
positions (DM). Native p53 and its derivative acetylation mu-
tants were expressed in the p53-null cell line, H1299, via a tetra-
cycline-regulated promoter (see Fig. 4 F and Fig. S1 C, available 
at http://www.jcb.org/cgi/content/full/jcb.200512059/DC1, for 
typical expression levels of these p53 proteins). Cells were 
treated with different DNA-damaging agents, and their cell cycle 
distribution was assessed (Fig. 2 A). In untreated cells, expres-
sion of native p53 produced an arrest, especially at the G1 phase, 
accompanied by a reduction of cells transiting throughout 
S phase, as expected. The cell cycle  profi les of cells harboring 
Figure 2. Different effects of p53 acetylation 
mutants on cell growth. (A) Cell cycle proﬁ le of 
H1299 cells expressing p53 proteins (indi-
cated at the top of panels). Cells were left 
 untreated or treated with 50 μM adozelesin, 
50 μM bizelesin, or 100 μM etoposide. Drugs 
were added 24 h after tetracycline addition, 
and cells were grown for an additional 24–48 h 
and then harvested and stained with propid-
ium iodide (shown in all panels) and with BrdU 
(not depicted), and their cell cycle proﬁ le was 
determined. (B and C) Tetracycline-induced 
H1299 cells were left untreated or treated with 
1 μM adozelesin for 4 h. Cells were exten-
sively washed and incubated in drug-free me-
dia but in the presence of tetracycline for an 
additional 24 h. Tetracycline was then re-
moved to shut off p53 expression, and cells 
were allowed to recover for 6–8 d, after which 
one dish was stained with Coomassie brilliant 
blue (B) and the remaining were used for cell 
counting (C). Error bars indicate SEM.
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p53 acetylation mutants were different in several ways: a higher 
percentage of cells expressing p53DM arrested in G1, whereas 
cells harboring p53Q373 arrested markedly in G2/M, suggesting 
that these residues predominantly infl uence the activity of p53 
on the G2 checkpoint. To rule out the possibility that these differ-
ences may be due to unique clonal characteristics of these p53 
cell lines, similar experiments were performed by using either 
additional individual clones or polyclonal mixtures. The analysis 
of the growth characteristics and viability of these cells produced 
substantially similar results (Fig. S1, A and B).
To understand how site-specifi c acetylation of p53 affects 
sensitivity to anti-tumor agents, cells were treated with the DNA-
damaging agents adozelesin, bizelesin, or etoposide. In drug-
treated cells, expression of p53Q320 activated the G1 checkpoint 
and conferred signifi cant protection from cell death compared 
with native p53-expressing cells, which underwent apoptosis 
when treated with bizelesin or etoposide. Quite in contrast, 
p53Q373 had a strong chemosensitizing effect, as the majority of 
cells bearing this mutant underwent apoptosis early after drug 
treatment. In cells harboring the mutant at all positions, the per-
centage of apoptosis was signifi cantly lower than that observed 
in both native- and p53Q373-expressing cells, suggesting that the 
mutation of K320 has a dominant effect in preventing cell death.
K320 acetylation favors resumption 
of proliferation and cell survival
Results presented thus far are consistent with the possibility that 
acetylation of residues around position 373 activates the apop-
totic pathway, whereas acetylation of K320 suppresses cell death. 
We then hypothesized that acetylation of K320 could function 
to disable or delay the apoptotic program elicited by p53, thus 
allowing cells to resume proliferation in conditions of moderate 
DNA damage once p53 signaling is extinguished. To test this, 
cells expressing native p53 or p53 acetylation mutants were 
pulsed with low concentrations of adozelesin for a short period 
of time in the presence of tetracycline. p53 expression was shut 
off by removing tetracycline from the media 24 h after drug 
treatment, and cell growth was monitored for several days there-
after (Fig. 2, B and C). In these conditions, untreated and drug-
treated cells expressing p53Q373 displayed a signifi cant loss of 
viability, whereas cells expressing p53Q320 were able to resume 
proliferation. In addition, cells expressing p53DM again dis-
played a phenotype intermediate between that exhibited by 
p53Q320 and -Q373. These results argue against a simple model 
in which the number of acetylated lysines controls p53-apoptotic 
activity in a dose-dependent manner. Rather, they suggest that 
the effects of acetylation are strictly position specifi c and place 
acetylation of K320 as a central event in favor of cell survival.
Site-speciﬁ c acetylation differentially 
inﬂ uences the interaction of p53 
with transcriptional coactivators 
and corepressors
Posttranslational modifi cations regulate p53’s interaction with 
other cellular proteins. We next asked whether acetylation infl u-
ences the association with factors known to bind p53, particu-
larly to coactivators and corepressors. p53 protein complexes 
isolated from native or p53 acetylation mutant–expressing cells 
were subjected to immunoblot analysis with antibodies recog-
nizing p300, PCAF, HDAC1, mSin3, and p53 itself. HDAC1 and 
mSin3 are components of a corepressor complex, which plays 
an important role in the ability of p53 to silence transcription of 
critical antiapoptotic promoters (Murphy et al., 1999). As shown 
in Fig. 3 A, the p53Q373 mutant coprecipitated a signifi cantly 
higher amount of p300 compared with native p53 and p53Q320 
and, conversely, p53Q320 was more effi cient in interacting with 
Figure 3. Interaction of cofactors with acetylated forms of p53 protein. 
(A) Nuclear extracts prepared from H1299 cells treated with tetracycline 
were immunoprecipitated with an anti-Flag antibody, eluted with Flag 
 peptide, and run on 4–20% gradient gels. The presence of p300, PCAF, 
HDAC1, and mSin3 was revealed by immunoblotting with speciﬁ c anti-
bodies. (bottom) Total p53 levels contained in the anti-Flag–speciﬁ c immuno-
precipitation. (B) H1299 cells expressing native p53 were treated with 
etoposide for the indicated times. Cell extracts were immunoprecipitated 
with the anti-Acp53K373–speciﬁ c antibody. The presence of p53, SIRT1/
Sir2, or HDAC1 in these reactions was revealed via immunoblots with spe-
ciﬁ c antibodies, as indicated at the side of each panel. The bottom panel 
represents 20% of the total amount of precipitated p53 protein. (C) Anal-
ysis of the interaction between truly acetylated forms of p53 and p300. 
A549 cells expressing WT p53 were treated for 16 h with 50 μM adoze-
lesin and immunoprecipitated with either Acp53K320 (lane 1) or Acp53K373 
(lane 2). These reactions were subjected to p53- and p300-speciﬁ c immuno-
blots. The total levels of p300 were determined with the C-20 (Santa 
Cruz Biotechnology, Inc.) antibody after immunoprecipitation, whereas 
p53 levels were detected from total extract (lane 3).
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PCAF, indicating that each acetylation cluster specifi cally modi-
fi es the interaction of p53 with distinct types of histone acetyl-
transferases. Further, p53Q373 coprecipitated higher amounts of 
HDAC1 than native p53 or p53Q320 (Fig. 3 A). To further sub-
stantiate these fi ndings, we studied the binding pattern of endog-
enously, “truly” acetylated p53 after treatment with etoposide. 
Consistent with data obtained with the acetylation mimics, 
 acetylated p53 detected with the anti–acetyl-K373–specifi c anti-
body coprecipitated a signifi cant amount of HDAC1 and SIRT1 
(Fig. 3 B). Interestingly, these deacetylase–p53 complexes were 
 detectable for at least 12 h after treatment, indicating that 
 acetylation of K373 can stabilize the interaction of p53 with 
deacetylase–corepressor complexes. Similarly, in A549 cells 
treated with adozelesin, truly acetylated p53 at K373 displayed 
a signifi cantly stronger affi nity for p300 compared with acetyl-
K320 p53 (Fig. 3 C, compare lanes 1 and 2). These data further 
support the notion that glutamine in place of lysine mimics the 
effects of constitutive acetylation and imply that acetylation of 
different sites selectively modifi es the affi nity of p53 for differ-
ent types of chromatin-remodeling enzymes.
Delineation of the genetic program elicited 
by differently acetylated forms of p53
p53 conveys complex cellular responses that are due in part to 
its ability to function as a transactivator and as a transrepressor. 
To understand how acetylation operates, we performed micro-
array analysis on cells expressing native p53, p53Q320, and 
p53Q373 (Table S1, available at http://www.jcb.org/cgi/content/
full/jcb.200512059/DC1). Approximately 40,000 probe sets 
were examined by using high-density oligonucleotides arrays at 
12 h after addition of tetracycline to the media. For this analysis, 
we applied a present call noise fi lter (one in six arrays), fold-
change thresholds (>2), and a p-value of <0.05 as our initial 
dataset for preliminary analysis and gene identifi cation, leading 
to further consideration of 27,000 transcripts. To more specifi -
cally identify genes regulated in an acetylation-dependent 
 manner, genes found in the array platform derived from cells 
expressing native p53 served as background, so that p53Q373 or 
-Q320 gene-expression patterns were directly compared with 
native p53. With this analysis, we determined that both p53Q320 
and -Q373 lead to an increase of a similar number of transcripts, 
whereas p53Q320 repressed 955 genes, which was signifi cantly 
less than the 1,576 transcripts repressed by p53Q373. Thus, 
p53Q373 is a stronger repressor than p53Q320, consistent with 
its ability to interact more effi ciently with HDAC1 and SIRT1/
mSir2 (Fig. 3). Further, in agreement with the observation that 
p53Q373 sensitizes cells to apoptosis, many of the genes found 
activated by this mutant promote cell death (i.e., APAF1, 
caspase 6, pig3, pig11, AMID, PCBP4, and IGFBP3), and 
a  signifi cant number of those repressed promote survival 
Figure 4. Characterization of the gene-
 expression pattern elicited by p53 acetylation 
mutants. (A) Clustering of genes regulated by 
p53 acetylation mimics. Probes corresponding 
to fold change >2 were hierarchically clus-
tered. Data from each probe are in the col-
umns, and each experiment is shown as 
a row. Red and green denote increased and 
decreased expression levels, respectively, 
with the intensity reﬂ ecting the magnitude of 
change. (B) Validation of microarray data by 
semiquantitative RT-PCR. To verify oligonucle-
otide microarray results, semiquantitative 
RT-PCR was used to estimate the amount of 
RNA from three altered genes in WT p53–, 
p53Q320-, and p53Q373-expressing cells (+). 
To ensure that clonal variability does not 
 contribute to the different levels of gene expres-
sion, mRNA was collected from H1299-WT, 
-Q320, and -Q373 cells in the absence of 
 tetracycline (−). Densitometry was performed 
using Fluor Chem 3.04A software (Alpha Inno-
tech Corp.) and normalized to the β-actin 
 signal. Fold changes represent the difference for 
each mRNA observed within each individual 
cell line. Each band detected in the absence 
of tetracycline was attributed an arbitrary value 
of 1 and compared with the band detected in the presence of tetracycline (lanes 1, 3, and 5 were compared with lanes 2, 4, and 6, respectively). 
(C) In vivo interaction of p53 with its DNA binding sites derived from different promoters. Untreated H1299 or H1299 treated with tetracycline were cross-
linked with formaldehyde and immunoprecipitated with a polyclonal antibody recognizing p53 (FL393). The amount of p53 proteins contained in these 
 immunoprecipitation reactions was normalized (E), such that similar amounts of DNA-bound p53 were used for sequence-speciﬁ c ampliﬁ cation of the 
 promoters of p21/WAF, PIG3, BAX, and p53AIP1. (D) H1299 cells were treated with tetracycline to induce WT p53 protein and then subjected to ChIP. 
Acetylated p53 was precipitated by using antibodies directed against Acp53K320 or Acp53K373/K382, whereas total p53 was precipitated with the polyclonal 
p53 antibody. Promoter binding was assessed as described in C. Input represents 2% of the total DNA content used for precipitation. (E) Equalization of 
p53 proteins used for the ChIP assays in C. p53 levels in each cell line were predetermined after DNA–protein cross-linking by direct immunoblot and 
 before the immunoprecipitation reaction (not depicted). The amounts of cell extract were then adjusted based on this preliminary assessment, so that equiva-
lent amounts of each acetylation mutant were subjected to immunoprecipitation and subsequent PCR ampliﬁ cation. The two panels show typical levels of 
p53 proteins after this equalization, derived from two different experiments. (F) H1299 cells were left untreated (time 0) or were treated with tetracycline 
for 12 and 24 h. The type of p53-expressing cell line is indicated at the top of the panels. Cell lysates were prepared and subjected to immunoblots with 
antibodies recognizing p53, p21/WAF, Bax, and actin.
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(i.e., survivin, API5, BIRC3, and IL31RA). The behavior of 
p53Q320 was, instead, opposite. For example, several of the 
proapoptotic genes activated by p53Q373 were repressed by 
p53Q320 (i.e., APAF1 and pig11) relatively to native p53 and, 
vice versa, some antiapoptotic genes repressed by p53Q373 
were activated by p53Q320 (i.e., survivin, TRAF2, AATF, and 
BIRC4). Numerous other genes were also conversely expressed 
between p53Q320 and -Q373 (e.g., cyclin B1; Table S1, bold). 
To gain a further unbiased analysis of this phenomenon, a “heat 
map” was generated, which demonstrated differential, if not 
 contrasting, gene-expression patterns between p53Q320 and 
-Q373 (Fig. 4 A). To validate the gene changes identifi ed with the 
microarray platform, semiquantitative PCR was also performed 
on various relevant apoptotic- and growth arrest–related genes, 
some of which are shown in Fig. 4 B. This approach confi rmed 
that the regulation of previously known p53 targets, such as pig11 
and APAF1, or of new p53-regulated genes like Jagged2, was 
signifi cantly different depending on the site of the mutation.
Although we cannot completely exclude the possibility 
that at least some of these changes are an epiphenomenon, re-
fl ecting events secondary to p53 activation, many of the relevant 
genes differentially modulated by p53Q320 and -Q373 are well-
known primary targets of p53, for example, APAF1, pig11, 
 survivin, caspase 6, mdm2, and cyclin B1. In addition, a large 
number of newly identifi ed genes that we found up-regulated in 
the microarray platform contain p53 binding elements (Table I), 
thus suggesting that they might be direct p53 targets. In addition, 
this approach indicated that p53Q373, unlike p53Q320, predom-
inantly controls the expression of genes that regulate apoptosis.
Acetylation of various sites differentially 
inﬂ uences the interaction of p53 
with downstream promoters
Data based on the microarray analysis suggested that acetylation 
of K320 or K373 may lead to direct p53 binding onto different 
types of promoters. However, previous studies showed that si-
multaneous acetylation of multiple COOH-terminal lysines en-
hances the DNA binding activity of p53 on typical DNA binding 
elements (Gu and Roeder, 1997; Luo et al., 2004). In light of our 
results, we decided to investigate how each of the acetylation 
clusters individually infl uences p53–promoter interactions. The 
DNA binding properties of acetylation mutants and of truly acet-
ylated p53 were studied in vivo in chromatin immuno precipitation 
(ChIP) assays. To assess the infl uence of chro matin on the abil-
ity of p53 to interact with its DNA consensus sites, we also per-
formed electrophoretic mobility shift assays (EMSAs) with 
Table I. Putative p53 binding sites in the genes up-regulated by p53 acetylation mimics
Gene length Site location Score Putative p53 binding site
Q320
 axl 62851 47804 100 G G G C T T G T C C  A C A T G G G C T   G G G C A T G T C T 
 cdk2 25017 9808 100 A A A C T T G T C T  A G C C C C C A A G A A C C  A A A C T T G C C T 
 rad9 27671 22729 93.66 A C A C A A G T C C  A G A T A T A G A C A G  A A A C T T G C C C 
 atm 162402 89128 93.56 A A G C A T G T T T  A A G A  A C A C T T G T T C 
 mad2l1 27376 25528 93.02 A A T C T A G C T C  C T T A T T T T C  A A A C A T G T T T 
 mcm5 44646 23519 93.01 A G G C A A G C T C  T G T C C T C A T T G C T  A G G C A A G A C C 
 mcm6 55966 41522 90.9 A G G C A T G C T T T A A T A C A A G T G A T A  T G A C T T G T T A 
 birc5-survivin 30454 15287 90.13 A A G C A T G C T G  T G A G A  G A G C T T G T C A 
 cdc6 34178 26674 90.89 A G A C T T G C C T  G T G G C T A G C T A 
 tnfrsf6b-dcr3 64663 13579 88.94 A A G C T T G T C T C A G G G  C A G C T T G T G T 
 cdc25a 51427 13156 93 A G T C A A G T C T  C A C T A T G T T G C C C C   A G G C T T G T T T 
 cdc2 35523 1135 90.93 T A A C A A G C T C  C T T T C A T C A G T C C C  A A G C A A G C C A 
 skp2 51917 41500 95.85 A A A C T A G T T T A A A T T G A  T G A C T T G T T C 
 jun 23255 3530 88.92 T G G C T T G G C T G G G C T G G G C C A T G  A G A C T A G T T T 
 cdkn2c 25945 6870 87.82 A G G C A T G G T G  . G A G C A T G C C T 
Q373
 csnk1g1 148281 12563 100 G G A C T T G C C T  G T A G T C A G A A   G A A C T T G T C T 
 pig11 40531 13335 93.59 G C A C A A G C C T T T T A A G T C A T   G A G C T A G T C C 
 pml 68790 1318 93 A G A C T T G C T T T A  A G G C A A G A T C 
 igfbp3 29032 25147 92.04 T G A C T A G C T T  C T T T C A C T  T A G C A T G T T T 
 jagged2 47019 18872 89.85 G A G C A T G T T G  G G G T G T G T G G A T G  G A G C A T G T T G 
 jag1 56265 29477 82.78 A T A C A T G C T T G C T T A   T T G C A A G C C T 
 pig3 27431 8069 83.82 A G A C A T G T T T T T T G C C C T A A C A A G T G A 
 ak1 28274 1838 83.45 T G G C C A G C T C  C A A A C T T A C  A G A C T T G T C T 
 apaf1 110193 79794 88.99 G G G C A A G C C C  A G A C A  C C A C T T G T T T 
 casp6 34733 18886 88.89 T G G C T T G T T C A A A G G  A G A C A A G T G T 
 gas6 32013 11571 82.21 C G T C T T G C C C  T T C A G A A A C A T T G T A G A C T T G T A T 
Genes that were activated by p53Q320 or -Q373 in the microarray platform were researched in a p53 database generated at The Rockefeller University (http://linkage.
rockefeller.edu/p53). This database catalogues putative p53 DNA binding elements in 2,583 human genes and 1,713 mouse homologues on the basis of a newly 
developed p53MH algorithm. Genes containing putative p53 consensus sites and relative scores are shown. Gene length represents the combined base-pair length 
of the promoter and gene sequence. Site location represents the position within the gene length where the listed binding sequence begins. The consensus p53 binding 
sequence is PuPuPuC(A_T)(T_A)GPyPyPy.
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in vitro–purifi ed p53 (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200512059/DC1). A fi rst observation arising 
from these experiments was that native p53 bound to the endog-
enous promoter of p21/WAF with signifi cantly higher affi nity 
compared with the PIG3, BAX, or p53AIP1 promoters (Fig. 4 C). 
Results obtained with EMSAs essentially recapitulated those 
seen with the ChIP assays and indicated that p53 possesses 
 substantially different intrinsic affi nity for its DNA binding 
 elements. Noticeably, both p53Q320 (Fig. 4 C) and its truly 
acetylated counterpart immunoprecipitated with the anti–acetyl-
320 antibody (Fig. 4 D), bound to the high-affi nity p21/WAF 
promoter more effi ciently than native p53 or p53Q373. Con-
versely, p53Q373, as well as endogenously acetylated p53 at po-
sition K373, interacted better with the low-affi nity proapoptotic 
promoters of BAX (Fig. 4, C and D), PIG3, and p53AIP1 (Fig. 
4 C), compared with other p53 proteins. It is important to note 
that both the EMSAs and ChIP assays were performed in condi-
tions in which p53 levels were equalized (Fig. 4 E). Thus, these 
differences refl ect acetylation-mediated changes in the intrinsic 
p53’s DNA binding affi nity. Furthermore, the different promoter 
binding pattern of p53 acetylation mutants resulted in coherent 
changes in the expression levels of corresponding encoded prod-
ucts, as demonstrated by the different protein levels of Bax and 
p21/WAF in these cell lines (Fig. 4 F). Based on these data, we 
infer that acetylation of K373 enhances the interaction of p53, 
particularly with low-affi nity proapoptotic promoters.
Acetylation inﬂ uences p53 
nuclear retention and is coupled 
to site-speciﬁ c phosphorylation
The aforementioned results offer a plausible molecular basis for 
the proapoptotic activity exhibited by p53Q373; however, they 
do not completely explain the biological effects of the mutant at 
position 320. Because K320 is located in a previously  identifi ed 
nuclear localization signal (Liang and Clarke, 2001), we sus-
pected that acetylation of this residue might affect the subcellular 
localization of p53. In fact, as shown in Fig. 5, the p53 acetyla-
tion mimic at position K320 was localized predominantly in the 
cytoplasm, whereas p53Q373 was almost exclusively nuclear 
(Fig. 5 A). The presence of the mutation at position 320 also 
partially placed p53Q373 off the nucleus, as argued by the cyto-
plasmic localization of p53DM. In addition, when lysines were 
replaced with arginine rather than with glutamine, both R320 and 
R373 mutants localized in the nucleus (Fig. 5 B), indicating that 
neutralization of the positive charge of lysine interferes with nu-
clear accumulation of p53. Surprisingly, however, the increased 
cytoplasmic concentration of p53Q320 and -DM is not sustained 
by an increase in nuclear import but rather by an accelerated nu-
clear export. This is argued because treatment with leptomycin B, 
which blocks the activity of the exportin protein Crm1 (Fukuda 
et al., 1997), resulted in net nuclear accumulation of both mutants 
(Fig. 5 C). To further validate these results, two additional sets 
of experiments were performed. First, we studied the subcellular 
distribution of truly acetylated p53 in H1299 cells treated with 
adozelesin, which enhances the levels of K320 acetylation (Fig. 
6 A). Treatment with adozelesin increased the cytoplasmic frac-
tion of p53, and such fraction reacted with the anti–acetyl-320 
antibody. Second, we determined the localization of p53 after 
overexpression of PCAF or of p300, which acetylate K320 and 
K370/372/373, respectively.  Overexpression of PCAF resulted in 
increased cytoplasmic levels of p53 (Fig. 6 B), in contrast to over-
expression of p300, where p53 remained substantially nuclear.
Figure 5. Acetyl-mimic Q320 alters the nuclear-cytoplasmic shuttling of p53. 
(A and B) Tetracycline-induced H1299 cells were grown on glass cover-
slips, and 24 h later cells in A and B were stained with an anti-p53 poly-
clonal antibody (red) and with DAPI (blue). (C) Tetracycline-induced cells 
expressing p53Q320 and p53DM were grown in the presence of lepto-
mycin B and subjected to indirect immunoﬂ uorescence.
Figure 6. Acetylation of K320 increases the cytoplasmic localization of p53. 
(A) Tetracycline-induced WT p53–expressing H1299 cells were left un-
treated or were treated for 16 h with 50 μM adozelesin and then stained 
with a polyclonal antibody recognizing 320-acetylated p53 (Ac-320; red), 
a monoclonal antibody recognizing total p53 (green) and DAPI. (B) WT 
p53–H1299 cells were transfected with a PCAF or a p300 expression vec-
tor for 24 h and then stained with DAPI and with antibodies recognizing 
p300, p53, or PCAF, as indicated at the top of each panel.
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The observation that K320 acetylation might place p53 
off the nucleus by accelerating nuclear export led us to investi-
gate the possible cross-talk between acetylation and phosphory-
lation of serine 15 (S15), which has been implicated in nuclear 
accumulation (Zhang and Xiong, 2001). As shown in Fig. 7 A, 
S15 phosphorylation was almost undetectable in cells express-
ing p53Q320, whereas the p53Q373 mutant was hyperphos-
phorylated at this residue compared with other p53 proteins, 
suggesting that acetylation and phosphorylation might be func-
tionally linked. To assess whether other specifi c combination 
patterns of acetylation and phosphorylation do exist, we exam-
ined the phosphorylation state of S392 and S46. S392 phos-
phorylation increases the stability and the nuclear localization 
of p53 (Kim et al., 2004), whereas phosphorylation of S46 is 
specifi cally involved in mediating the interaction of p53 with 
the promoter of the proapoptotic gene p53AIP1 (Oda et al., 
2000). We found that p53Q373, but not p53Q320, was hyper-
phosphorylated at both sites.
Thus, K320 acetylation negatively interferes with the phos-
phorylation and the activity of the nuclear export domain of p53, 
whereas K373 acetylation enhances the phosphorylation of sites 
involved in regulation of retention and accumulation of p53 in the 
nucleus, as well as in p53 binding to proapoptotic promoters.
Modiﬁ cations of K320 and K373 induce 
conformational changes in the NH2 
terminus and DNA binding domain of p53
As a whole, our results imply that individual acetylation of ly-
sines 320 and 373 of p53 has general, yet differential, effects on 
the intrinsic DNA binding activity and on the ability to interact 
with cellular proteins and infl uences other key posttranslational 
modifi cations, such as phosphorylation. We were interested in 
understanding, at a mechanistic level, how these acetylation 
events may affect so many important p53 functions. We hypoth-
esized that modifi cations of K320 or K373 induce conforma-
tional changes that in turn infl uence multiple protein–protein 
interactions. To test this, we assayed the ability of p53Q320 and 
-Q373 to interact with antibodies recognizing epitopes located 
within spatially distant portions of p53 (Fig. 7, B and C). 
We used the p53 antibody DO-1, which binds to amino acids 
20–25 in the NH2 terminus (B-1); the PAb421 antibody, which 
recognizes a COOH-terminal epitope located between amino 
acids 372–381 (B-2); and the PAb240 antibody, a typical con-
formational antibody that recognizes residues 213–217 within 
the DNA binding domain (B-3). This latter epitope becomes ex-
posed when p53 is in an inactive mutant conformation or when 
WT p53 is bound to DNA (McLure and Lee, 1996). To assess 
the accessibility of these epitopes in the absence of other 
changes, native or acetylation mutant forms of p53 were puri-
fi ed in vitro to near homogeneity from insect cells infected with 
recombinant baculoviruses, and each protein was immuno-
precipitated with limiting or saturating amounts of antibodies. 
The purity of these preparations is shown in Fig. S3 (available 
at http://www.jcb.org/cgi/content/full/jcb.200512059/DC1). 
The results of these experiments were striking. Indeed, all three 
epitopes were more accessible by their specifi c antibody in the 
case of p53Q320. The increased accessibility of the PAb240 
 epitope can particularly explain the lesser binding of this mu-
tant to low-affi nity promoters, as exposure of these residues in-
dicates a partially denatured conformation. In contrast, p53Q373 
completely disrupts reactivity with the PAb421, probably be-
cause the PAb421 epitope spans within this region. Importantly, 
no signifi cant differences were observed when p53 proteins 
were immunoprecipitated with a goat polyclonal antibody 
(N-19; B-4) or were subjected to direct immunoblot after p53 
had been denatured in SDS-PAGE (C-2).
Thus, in vitro, mutations of K320 and K373 impart con-
formational changes that modify the accessibility of epitopes 
located within the NH2 terminus, the central portion, or the 
COOH terminus of p53. Likewise, in vivo, acetylation- mediated 
changes in the availability of these sites might explain differen-
tial interactions with cellular factors, including coactivators and 
corepressors, or kinases and phosphatases that in turn infl uence 
transcription and phosphorylation, respectively.
Discussion
Why so many acetylation sites?
Our results are consistent with a model whereby acetylation of 
lysines 320 and 373 acts as a fi nely tuned sensor-effector sys-
tem that enables p53 to coordinate gene-expression patterns in 
response to DNA damage (Fig. 8). We have demonstrated that 
various p53 acetylation mutants, as well as truly acetylated p53 
(Fig. 4), possess different intrinsic affi nities for their  downstream 
Figure 7. Phosphorylation proﬁ le of p53 acetylation mutant proteins. 
(A) Cell extracts derived from tetracycline-induced H1299 cells expressing 
p53, p53Q320, or p53Q373 were subjected immunoblot with antibodies 
recognizing total or S15-phosphorylated p53. p53 levels were equalized 
among the different cell lines (bottom), so that similar amounts of each p53 
acetylation mutant was probed with anti-phosphorylation–speciﬁ c anti-
bodies. S46 or S392 phosphorylation was detected via immunoprecipita-
tion with a p53 polyclonal antibody, followed by immunoblot with anti-p53 
antibodies directed against phospho-S46 or -S392. Fold induction for 
each phosphorylation site was determined by densitometry by using Fluor 
Chem 3.04A software, whereby cells expressing native p53 were attrib-
uted an arbitrary value of 1 and signals were normalized for total p53 
 levels. (B) WT p53, p53Q320, and p53Q373 were puriﬁ ed from baculo-
virus-infected cells and immunoprecipitated (IP) with different antibodies, 
each recognizing a different epitope, at the concentrations indicated at the 
top of each panel. The products of these immunoprecipitations were sub-
jected to immunoblot (IB). The combination of antibodies used is indicated 
at the left side of each panel. (C) p53 mutants puriﬁ ed from baculovirus-
 infected cells were visualized via Coomassie blue staining (1) or by direct 
immunoblot with the DO-1 antibody (2).
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promoters and that acetylation of residues around position K373 
is necessary, particularly for binding to low-affi nity proapop-
totic promoters, such as BAX, both in vitro and in vivo (Fig. 4 
and Fig. S2). It is important to note that although the expression 
levels of p53Q373 were consistently twofold higher than those 
of other p53 proteins (Fig. 4 and Fig. S1) in conditions in which 
p53 levels were predetermined and equalized, such as in 
EMSAs (Fig. S2), in ChIP assays (Fig. 4), and in the phosphory-
lation studies (Fig. 7), p53Q373 interacted more strongly with 
proapoptotic promoters and was hyperphosphorylated com-
pared with WT p53 or p53Q320. Thus, these changes refl ect 
qualitative differences in the behavior of this mutant. In light of 
these data, p53Q373-mediated activation of proapoptotic pro-
moters might depend on a combination of effects, specifi cally, 
a direct enhancement of the intrinsic DNA binding affi nity, hy-
perphosphorylation of strategic residues, and an increase in p53 
nuclear retention that allows occupancy of “hard-to-reach” and 
low-affi nity promoters. In contrast, we found that p53Q320 in-
teracted effi ciently with the high-affi nity p21/WAF promoter 
but to a lesser extent with the promoters of BAX, p53AIP1, and 
PIG3. This correlated with a PAb240+ conformation, indica-
tive of a partially denatured confi guration, as well as with de-
creased phosphorylation of residues that favor nuclear retention 
of p53. We interpret these data to conclude that the effects of 
K320 acetylation rely, at least in part, on its accelerated nuclear 
export (Figs. 5 and 6) and different conformation (Fig. 7), both 
of which could prevent p53 from reaching nuclear concentra-
tions and a confi guration necessary to effi ciently saturate low- 
affi nity promoters. We have further shown that K373 acetylation 
stabilizes the interaction of p53 with p300, HDAC1, and SIRT1/
Sir2 (Fig. 3). These molecular features were linked to an in-
crease in the total number of repressed genes by p53Q373 com-
pared with p53Q320 and with qualitative differences in the 
pattern of activated genes (Table S1). Expression of p53Q320, 
which interacts with PCAF but has signifi cantly less affi nity for 
p300 (Fig. 3), appeared instead to correlate with a lower thresh-
old of activation and with a distinct pattern of gene expression. 
In addition, an unbiased “heat map” of genes regulated by the 
two acetylation mutants clearly demonstrated differential, if not 
contrasting, gene-expression patterns between p53Q320 and 
-Q373 (Fig. 4 A). Collectively, our results imply that each of the 
various clusters of acetylation regulates p53 distribution in dif-
ferent cell compartments and chromatin domains and acts as an 
interaction platform for various types of chromatin-remodeling 
enzymes to activate specifi c sets of genes.
The aforementioned differences in the biochemical prop-
erties of p53 acetylation mutants are physiologically relevant. 
Indeed, cells expressing p53Q320 were capable of promoting 
cell survival and resumption of proliferation in conditions of 
moderate DNA damage, unlike those harboring p53Q373, 
which were irreversibly committed toward apoptosis (Fig. 2). 
Thus, in view of the DNA binding properties of the correspond-
ing mutants, it seems legitimate to speculate that acetylation of 
K320 enables cells to tune the expression of various p53 target 
genes in a way that enhances the ability of cells to survive if the 
damage does not accumulate to catastrophic levels. While this 
work was in progress, a report showed that p53 activates a cell 
cycle checkpoint that responds to glucose availability and pro-
motes survival (Jones et al., 2005). In keeping with our fi ndings, 
these observations lead to the important conclusion that the cell 
cycle and death pathway are under the control of a subpopula-
tions of p53 with very distinct biochemical properties.
As noted previously, the p53 protein of D. melanogaster 
(dp53) differs from its human counterpart because of its exclusive 
role in promoting apoptosis (Brodsky et al., 2000; Ollmann et al., 
2000). Accordingly, unlike mammalian cells, D. melanogaster 
does not possess some of the pathways needed for recovery after 
p53 activation, as judged by the absence of genes encoding for 
key negative regulators of p53 (e.g., MDM2). Signifi cantly, our 
analysis of the degree of conservation of the different p53 acety-
lation clusters between mammalian and D. melanogaster p53 
(Fig. 9) showed that dp53 possesses a COOH-terminal domain 
with homology to the stretch of amino acids containing acety-
lated residues around position 373 of human p53, as noted by 
others (Brodsky et al., 2000), but no detectable K320 homology. 
Thus, regulation of p53 activity via K320 acetylation might have 
evolved in higher eukaryotes to suppress the apoptotic program 
and to allow recovery after damage. We postulate that this refl ects 
the necessity of complex multicellular organisms to spare the life 
of tissues with limited proliferation potential. In strong support 
of this interpretation, we have now shown that K320 acetylation 
is particularly favored in neuronal cells after injury, where it regu-
lates the expression of genes specifi cally involved in neuronal 
survival and regeneration (unpublished data).
The COOH-terminal tail of p53 and a p53 
acetylation code
It is becoming clear that the COOH-terminal region of p53 is a 
target of numerous additional posttranslational modifi cations, 
Figure 8. p53 cassettes, created by combinations of posttranslational 
modiﬁ cations and protein–protein interactions, control cell fate. By analogy 
with the “histone code” hypothesis elaborated by Strahl and Allis (2000) 
and based on data shown in this study, we propose that speciﬁ c combina-
tions of posttranslational modiﬁ cations generate distinct p53 cassettes that 
direct p53 toward precise cellular functions. These p53 cassettes, in addi-
tion to directly inﬂ uencing key biochemical properties of p53, such as its 
DNA binding afﬁ nity, also interact speciﬁ cally with effector proteins that 
participate in deciphering and eliciting a particular response. We envision 
that these combination cassettes may exist for many p53 posttranslational 
modiﬁ cations and establish a modular link between multiple upstream reg-
ulators of p53 and downstream events.
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such as phosphorylation, ubiquitination, sumoylation, and meth-
ylation (Bode and Dong, 2004). The similarity between the post-
translational modifi cations that exist in the histone tail and in the 
p53 COOH-terminal domain is intriguing. In the case of his-
tones, it has been proposed that different patterns of such modi-
fi cations, acting alone or in combination on one or more tails, 
establish a “histone code” that is deciphered by other proteins to 
coordinate downstream events (Strahl and Allis, 2000). In this 
model, the recruitment of nucleosome-modifying enzymes and 
of effector molecules by such “histone cassettes” will execute 
the code by changing local chromatin structure. For p53, the 
challenge for further studies will be to understand whether spe-
cifi c combinations of posttranslational modifi cations do exist 
that modify and expand the ability of this protein to regulate 
gene expression in a manner similar to that proposed for the his-
tone tail. Experiments presented here suggest that mutations of 
each of the two lysine clusters is associated at the very least with 
a different phosphorylation pattern in the NH2-terminal region 
of p53, with a different ability to interact with coactivators and 
corepressors, and with a different gene-expression profi le. More-
over, in conditions whereby the activity of each acetylation mu-
tant was studied independently, such as in the H1299 cell lines, 
we were able to trace an effect of each acetylation cluster on 
apoptosis or on the G1 and G2 checkpoints (Fig. 2). This fi nd-
ing, together with biochemical studies on the phosphorylation 
state and interaction profi le of p53 acetylation mutants, supports 
the idea that the biological activities of p53 may be dictated by 
multiple cassettes, each interacting with specifi c effectors and 
containing well-defi ned combination patterns of posttransla-
tional modifi cations. This interpretation might explain why so 
many posttranslational modifi cations target p53 (Fig. 8).
Implications for chemotherapy
It is well known that certain organs, such as the central nervous 
system, kidney, heart, liver, and lung, are naturally radio 
 resistant, and there is good evidence that p53 is an important 
determinant of tissue-specifi c radio sensitivity (Gudkov and 
Komarova, 2003). We have shown that in a lung tumor cell line, 
the extent of K320 or K373 acetylation is qualitatively and 
quantitatively infl uenced by the type and extent of DNA  damage. 
It is also possible that the extent of acetylation of each of these 
sites is determined in a tissue-specifi c manner by the local avail-
ability of acetylases or deacetylases. Based on the fact that 
 expression of p53Q320 allows for resumption of proliferation 
after DNA damage, we predict that strategies aimed at enhanc-
ing acetylation of K320 could foster the development of com-
pounds that protect peripheral tissues from toxicity during the 
course of chemotherapy.
Materials and methods
Cell lines, transfections, and the generation of the H1299 
tetracycline-inducible cells
H1299 and A549 lung carcinoma cells were grown in DME supplemented 
with 10% FCS and 2 mM L-glutamine. The p53 mutants used for the 
tetracycline-inducible system were constructed by using a Pfu-polymerase–
based, site-directed mutagenesis (Stratagene), followed by cloning of the 
ampliﬁ ed cDNAs into the pCDNA/TO4 vector (Invitrogen). The primers 
used for mutagenesis were as follows: p53Q320, 5′-C C C C A G C C A A A G C-
A G A A A C C A C T G G A T G G A G A A and p53Q373, 5′-A G C C A C C T G C A G T-
C C C A A C A G G G T C A G T C T A C C . p53DM was created with two consecutive 
rounds of site-directed mutagenesis. A Flag-encoding sequence was fused 
in frame to the NH2 terminus of p53 to facilitate immunodetection of 
the protein. Transfections were performed by using either Lipofectamine 
(Invitrogen) or FuGENE 6 (for coverslips; Roche). Full-length PCAF and 
HA-tagged p300 were expressed from pCDNA vectors. Cells were plated 
at 20–40% conﬂ uence 12–18 h before transfection. Cells were exposed to 
the transfection reagent for 16 h, washed twice with PBS, and refed with 
complete medium for an additional 24 h. Adozelesin and bizelesin were 
provided by T. Beerman (Rowell Park Cancer Institute, Buffalo, NY).
In vivo DNA binding assays
ChIP assays were performed as described elsewhere (Ogawa et al., 
2002). The primers used for ampliﬁ cation of p53-responsive elements 
were as follows: p21, 5′-T C A C C A T T C C C C T A C C C C A T G C T G C T C and 
3′-A A G T T T G C A A C C A T G C A C T T G A A T G T G ; BAX, 5′-A G C T C A T G C C T-
G T A A T C C C A G C G C T and 3′-A A A T A G C A T G C T T C C A G G C A G G A C G T ; 
P53AIP1, 5′-A G C T G A G C T C A A A T G C T G A C and 3′-C C A A G T T C T C T G C T-
T T C ; and PIG3, 5′-C A G G A C T G T C A G G A G G A G G C G A G T G A T A A G and 
3′-G T G C G A T T C T A G C T C T C A C T T C A A G G A G A G .
In vitro puriﬁ cation of p53 and EMSAs
p53 was puriﬁ ed from 10 dishes of SF21 cells infected with recombinant 
baculoviruses expressing native or acetylation mutant p53. Cells were har-
vested and lysed in extraction buffer (20 mM Hepes, pH 7.5, 0.5 M KCl, 
0.4 mM EDTA, 0.2% NP-40, 10 mM β-mercaptoethanol, 0.1 mM PMSF, 
and 10 μg/ml pepstatin), incubated on ice for 20 min, and centrifuged at 
14,000 g for 30 min at 4°C. p53 was puriﬁ ed by using a anti-Flag immuno-
afﬁ nity column (Sigma-Aldrich) in the presence of 0.5 M KCl, extensively 
washed, and eluted with the Flag peptide. EMSAs were performed in a 
30 μl total volume that contained buffer A (5× 100 mM Hepes, pH 7.9, 
125 mM KCl, 0.5 mM EDTA, 50% glycerol, and 10 mM MgCl2); buffer B 
(10× 10 mM spermidine, 40 mM DTT, 1.2% NP-40, and 2 mg/ml BSA); 
10 ng of double-stranded poly(d[I-C]); 50 ng of labeled oligonucleotide; 
and 50, 75, or 150 ng of p53. Reactions were incubated with the probe at 
room temperature for 20–40 min and run on native 6% polyacrylamide gels, 
which were run at room temperature until the xylen-cyanol blue reached 
6 cm from the bottom of the gel. The oligonucleotides used were as follows: 
p21/WAF, 5′-T C T G G C C A T C A G G A A C A T G T C C C A A C A T G T T G A G C T C T-
G G and 3′C C A G A G C T C A A C A T G T T G G G A C A T G T T C C T G A T G G C C A G A ; 
Gadd45, 5′T C T G T G G T A C A G A A C A T G T C T A A G C A T G C T G G G G A C T G C C 
and 3′-G G C A G T C C C C A G C A T G C T T A G A C A T G T T C T G T A C C A C A G A ; and 
Bax, 5′A A T T C G G C T A C C T C A C A A G T T A G A G A C A A G C C T G G G C G T G G-
G C T A T A T T G T A G C G A A T and 3′-A T T C G C T A C A A T A T A G C C C A C G C C C A G-
G C T T G T C T C T A A C T T G T G A G G T A G C C G A A T T .
Immunoprecipitations and immunoblots
Preparation of cell extracts and immunoprecipitations were performed as 
previously described (Avantaggiati et al., 1997). Antibodies used in this 
study were for p53 (FL393 and N-19 [Santa Cruz Biotechnology, Inc.] and 
Ab-1 and Ab-6 [Calbiochem]), S15-, S46-, and S392-phospho-p53 (Cell 
Signaling Technology), Acetyl-320-, Acetyl-373-, and Acetyl-373/382-p53 
Figure 9. Conservation of K373 but not K320 
between human and D.  melanogaster p53. 
 Human and D. melanogaster p53 were aligned 
using LALIGN from GeneStream (http://www.
eng.uiowa.edu/~tscheetz/sequence-analysis/
examples/LALIGN/lalign-guess.html). Identical 
residues are shaded in gray, whereas con-
served residues are colored in blue. K320 and 
K373 are indicated on human p53.
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(Upstate Biotechnology), PCAF (E8; Santa Cruz Biotechnology, Inc.), p300 
(N-15; Santa Cruz Biotechnology, Inc.), p21 (WAF1/Ab-5; Calbiochem), 
mSin3 (AK-11; Santa Cruz Biotechnology, Inc.), Sir2 (7342; Abcam), Bax 
(anti-Bax/NT; Upstate Biotechnology), and actin (I19; Santa Cruz Biotech-
nology, Inc.). Proteins were detected by using a chemiluminescence-based 
system (Pierce Chemical Co.) according to the manufacturer’s instructions.
Indirect immunoﬂ uorescence
The H1299 cells were plated on glass coverslips, ﬁ xed in 4% paraformal-
dehyde, and permeabilized by addition of 0.1% Triton X-100/PBS  solution. 
Cells were stained using antibodies directed against p53 (FL393), PCAF 
(E-8), or p300 (N-15) and then stained for DNA content (DAPI; Invitrogen). 
The appropriate ﬂ uorescent secondary antibodies were obtained from 
 Invitrogen. Where indicated, cells were treated with 5 ng/ml leptomycin B 
(Sigma-Aldrich) for 24 h. Cells were visualized using a microscope 
 (Axiovert 200; Carl Zeiss MicroImaging, Inc.) with either a 40× or 60× 
objective. Images were acquired using a camera (Axio; Carl Zeiss 
 MicroImaging, Inc.). Analysis of different Z stacks was performed using the 
AxioVision 3.0 software (Carl Zeiss MicroImaging, Inc.).
Microarrays
The cDNA microarrays were performed at the Children’s National Medical 
Center. H1299 cells expressing WT p53, p53Q320, or p53Q373 were 
harvested for total RNA extraction 24 h after the addition of tetracycline. 
7 μg total RNA was used for cDNA and biotinylated cRNA synthesis. 
 Expression-proﬁ ling analysis was performed using the HG-U133 human 
high-density oligonucleotide microarray (Affymetrix, Inc.). Each GeneChip 
was used for a single hybridization with RNA isolated from one cell line 
from a single experiment. The total number of samples was six.
Expression proﬁ ling was performed as described previously and 
 fulﬁ lled all stringent quality-control measures as detailed previously 
(Di Giovanni et al., 2005). We used two normalization processes: one for 
chip–chip comparisons (scaling factors) and one for gene–gene compari-
sons (normalization to the mean of the naive signal intensities for each 
gene). The scaling factor determinations were done using default algo-
rithms (MAS 5.0; Affymetrix, Inc.) with a target intensity of chip sector ﬂ uo-
rescence to 800.
We have recently shown that the use of MAS 5.0 signal intensity 
values, together with a present call noise ﬁ lter achieves an excellent 
signal/noise balance relative to other probe set analysis methods (dChip; 
robust multichip average [RMA]; Seo et al., 2004). Data analyses were 
limited to probe sets that showed one or more “present” (P “calls”) in the 
six GeneChip proﬁ les in our complete dataset. Data were analyzed and 
visualized using the GeneSpring software (Silicon Genetics). Initial data 
analysis also included a fold-change ﬁ lter of >2 increase or decrease rela-
tive to WT p53 (MAS 5.0). Functional classiﬁ cation was performed using 
DAVID software (http://apps1.niaid.nih.gov/david/upload.jsp).
For hierarchy and clustering analysis, the arrays were analyzed us-
ing the R statistics package (http://www.R-project.org) and the Affymetrix, 
Inc. library (Irizarry et al., 2003) of the Bioconductor software package. 
Expression values were determined using the RMA algorithm using the 
RMA function in the Affymetrix, Inc. library at its default settings. Genes 
that exhibited an expression change >2 relative to the control (WT p53) 
for at least one of replicates and one of the mutations were selected for fur-
ther analysis. These genes were then clustered using hierarchical clustering 
with “complete” agglomeration, and each cluster was further analyzed 
based on the known function of the genes contained in the cluster.
Semiquantitative PCR was performed using random hexamer 
priming for ﬁ rst-strand synthesis (SuperScript III; Invitrogen), followed by 
ampliﬁ cation of speciﬁ c genes with Taq polymerase and the following
primer pairs: Jagged-2, 5′-G T T G A C G C A C C T G T G G T T G T -3′ and 5′-C T T C-
A A T A C T G C C G C C G T C C -3′ (32 cycles); pig11, 5′-G G C T G A C A A C T G G C-
T G T C T T -3′ and 5′-A C A G G C C A T G T T G C T G T A T C -3′ (35 cycles); APAF-1, 
5′-T C T A C C T C T G C T G A C A A G A C -3′ and 5′-G T A G C A G C T C C T T C T T C T G A -3′ 
(35 cycles); and actin, 5′-G C T C G T C G T C G A C A A C G G C T -3′ and 5′-C A A A-
C A T G A T C T G G G T C A T C T T C T C -3′ (26 cycles).
Online supplemental material
Fig. S1 demonstrates that mixed populations of H1299–WT p53, 
p53Q320, p53Q373, or p53DM clones display similar cell cycle proﬁ les 
and viability compared with a single clone population after p53 protein 
 induction. In Fig. S2, EMSAs are used to study the DNA binding activity of 
p53 acetylation mimics in the absence of chromatin. Finally, Fig. S3 dem-
onstrates that the p53 protein puriﬁ ed from baculovirus-infected incest cells 
has a high level of purity. Table S1 depicts apoptotic and cell cycle–related 
genes inﬂ uenced in H1299 cells by the expression of the p53Q320 and 
-Q373 acetyl-mimics. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200512059/DC1.
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